结直肠癌：克服抗表皮生长因子受体（EGFR）治疗的耐药性——我们目前的进展如何？
Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?
作者信息
Schirripa Marta, Lenz Heinz-Josef
机构信息
Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, California 90033, USA.
出版信息
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):258-9. doi: 10.1038/nrgastro.2016.52. Epub 2016 Mar 23.
Abstract
In the past few years, the mechanisms leading to an acquired resistance to anti-EGFR monoclonal antibodies became an important topic in metastatic colorectal cancer research. In this commentary, we briefly summarize the latest update to this field by Arena and colleagues, and discuss promising new drugs and treatment strategies that might lead to overcoming secondary resistance.
摘要
在过去几年中，导致获得性抗表皮生长因子受体（EGFR）单克隆抗体耐药的机制成为转移性结直肠癌研究中的一个重要课题。在这篇述评中，我们简要总结了阿雷纳及其同事对该领域的最新进展，并讨论了可能有助于克服继发性耐药的有前景的新药和治疗策略。
相似文献
1
Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?结直肠癌：克服抗表皮生长因子受体（EGFR）治疗的耐药性——我们目前的进展如何？
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):258-9. doi: 10.1038/nrgastro.2016.52. Epub 2016 Mar 23.
2
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer.表皮生长因子受体（EGFR）催化结构域的体细胞突变与吉非替尼治疗结直肠癌
Ann Oncol. 2005 Nov;16(11):1848-9. doi: 10.1093/annonc/mdi356. Epub 2005 Jul 12.
3
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.三重阻断 EGFR、MEK 和 PD-L1 在 MAPK 信号通路持续激活和 PD-L1 过表达的结直肠癌模型中具有抗肿瘤活性。
J Exp Clin Cancer Res. 2019 Dec 16;38(1):492. doi: 10.1186/s13046-019-1497-0.
4
Colorectal cancer spheroid biobanks: multi-level approaches to drug sensitivity studies.结直肠癌细胞球生物样本库：药物敏感性研究的多层次方法。
Cell Biol Toxicol. 2018 Dec;34(6):459-469. doi: 10.1007/s10565-018-9423-3. Epub 2018 Feb 24.
5
The genomic landscape of response to EGFR blockade in colorectal cancer.结直肠癌中对表皮生长因子受体（EGFR）阻断反应的基因组格局
Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30.
6
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.BRAF非V600E突变对经治转移性结直肠癌患者抗表皮生长因子受体（EGFR）单克隆抗体治疗疗效的临床意义：综合癌症基因组学抗EGFR单克隆抗体生物标志物研究（BREAC研究）
Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.
7
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.PIK3CA 外显子 20 突变作为 KRAS 野生型转移性结直肠癌抗 EGFR 单克隆抗体耐药的潜在生物标志物：系统评价和荟萃分析。
Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29.
8
Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.转移性结直肠癌中对表皮生长因子受体抑制剂耐药性和敏感性的可塑性
Handb Exp Pharmacol. 2018;249:145-159. doi: 10.1007/164_2017_19.
9
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.结直肠癌患者对抗 EGFR 药物疗效的分子预测因子。
Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. doi: 10.2174/156800910790980205.
10
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.表皮生长因子受体荧光原位杂交检测可预测化疗难治性结直肠癌患者对西妥昔单抗的反应。
Ann Oncol. 2008 Apr;19(4):717-23. doi: 10.1093/annonc/mdm492. Epub 2007 Oct 31.
引用本文的文献
1
HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway.HOXB8通过激活STAT3信号通路介导大肠癌细胞对西妥昔单抗的耐药性。
Discov Oncol. 2024 Oct 29;15(1):603. doi: 10.1007/s12672-024-01440-z.
2
Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer.非编码RNA调节结直肠癌对表皮生长因子受体（EGFR）治疗的耐药性。
Front Oncol. 2022 Jan 17;11:801319. doi: 10.3389/fonc.2021.801319. eCollection 2021.
3
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer.FRESCO试验中按肝转移情况进行的亚组分析：比较呋喹替尼与安慰剂加最佳支持治疗用于中国转移性结直肠癌患者
Onco Targets Ther. 2021 Aug 11;14:4439-4450. doi: 10.2147/OTT.S307273. eCollection 2021.
4
Deoxycholic acid activates epidermal growth factor receptor and promotes intestinal carcinogenesis by ADAM17-dependent ligand release.脱氧胆酸通过 ADAM17 依赖性配体释放激活表皮生长因子受体并促进肠道肿瘤发生。
J Cell Mol Med. 2018 Sep;22(9):4263-4273. doi: 10.1111/jcmm.13709. Epub 2018 Jun 29.
5
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.呋喹替尼在既往接受过治疗的转移性结直肠癌患者中的安全性和有效性：一项Ib期研究和一项随机双盲II期研究。
J Hematol Oncol. 2017 Jan 19;10(1):22. doi: 10.1186/s13045-016-0384-9.
6
Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.转移性结直肠癌的新型疗法：分子见解与药物基因组学意义
Expert Rev Clin Pharmacol. 2016 Aug;9(8):1091-108. doi: 10.1586/17512433.2016.1172961. Epub 2016 Apr 14.
本文引用的文献
1
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.Sym004 是一种首创的抗 EGFR 抗体混合物，可克服结直肠癌中由 EGFR 细胞外结构域突变介导的西妥昔单抗耐药。
Clin Cancer Res. 2016 Jul 1;22(13):3260-7. doi: 10.1158/1078-0432.CCR-15-2400. Epub 2016 Feb 17.
2
Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.靶向转移性结直肠癌中表皮生长因子受体及其下游信号传导的当前和未来方法
Clin Colorectal Cancer. 2015 Dec;14(4):203-18. doi: 10.1016/j.clcc.2015.05.006. Epub 2015 May 29.
3
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.结直肠癌患者血液中的克隆进化及对表皮生长因子受体阻断的耐药性
Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1.
4
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.克服结直肠癌中对表皮生长因子受体（EGFR）疗法的耐药性
Am Soc Clin Oncol Educ Book. 2015:e149-56. doi: 10.14694/EdBook_AM.2015.35.e149.
5
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.MM-151，一种寡克隆抗 EGFR 抗体治疗药物，增强了 EGFR 网络的靶向性。
Mol Cancer Ther. 2015 Jul;14(7):1625-36. doi: 10.1158/1535-7163.MCT-14-0772. Epub 2015 Apr 24.
6
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.结直肠癌患者接受西妥昔单抗治疗时出现多种 EGFR 胞外突变。
Clin Cancer Res. 2015 May 1;21(9):2157-66. doi: 10.1158/1078-0432.CCR-14-2821. Epub 2015 Jan 26.
7
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.延长 RAS 突变和抗 EGFR 单克隆抗体在转移性结直肠癌中的生存获益：随机对照试验的荟萃分析。
Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12.
8
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.结直肠癌中 KRAS 突变的出现和抗 EGFR 治疗的获得性耐药。
Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.
9
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?西妥昔单抗在转移性结直肠癌患者中的再挑战：如何克服获得性耐药？
Ann Oncol. 2012 Sep;23(9):2313-2318. doi: 10.1093/annonc/mdr623. Epub 2012 Mar 5.
Zotero 插件